legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Vistin Pharma ASA Financial Results Announcement

Oslo, Norway – 15th of August 2025

Vistin Pharma ASA (VISTN) has officially released its financial results for the second quarter of 2025 today, reflecting significant growth figures compared to the previous year.

Revenue Insights

In the second quarter, Vistin Pharma reported revenue of MNOK 118, an increase from MNOK 106 in the second quarter of 2024. This impressive growth can be attributed to a remarkable 17% rise in sales volume. Furthermore, for the first half of 2025, total revenue reached MNOK 233, marking an 11% increase from MNOK 210 during the same timeframe last year. This upward trend in revenue indicates the company’s effective sales strategy and market demand for its products.

EBITDA Growth

The company also witnessed a notable rise in its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). The EBITDA for the second quarter ended at MNOK 30, increasing from MNOK 27 reported in Q2 2024. This represents an 11% growth driven primarily by higher sales volumes and a sustained focus on improving costs within the organization. Looking at the first half of the year, EBITDA stood at MNOK 60, compared to MNOK 48 in the same period of 2024, indicating a remarkable 27% increase. Such numbers underline the effectiveness of Vistin’s operational strategies.

Net Profit Analysis

The net profit for Vistin Pharma reached MNOK 40.2 compared to the previous year’s figure of MNOK 26.8 for the first half of 2025. This promising financial position underscores Vistin’s capacity to generate revenue and manage expenses efficiently.

Shareholder Returns

In June, Vistin Pharma declared a cash dividend of NOK 1.25 per share, validating its commitment to returning value to shareholders. This action demonstrates financial strength and future growth potential for the company, which is appealing to both current and potential investors.

Upcoming Conference Call

Shareholders and interested stakeholders are invited to participate in the second-quarter conference call scheduled for today, 15th of August at 8:30 AM (CET). This call will provide valuable insights into the financial performance and future outlook of Vistin Pharma.

Access to Conference Call

• Webcast: Access Here
• Telephone Conference (Online Registration): Register Here

The conference call will be conducted in English, catering to a broad audience.

Report and Presentation Availability

A detailed Q2 report and presentation will be available for all stakeholders. The report can also be accessed on www.vistin.com, ensuring transparency in the company’s operations and financial standing.

Contact Information

For further inquiries, please reach out to:

Alexander Karlsen
CFO
+47 97 05 36 21
[email protected]

This information is crucial and subject to the disclosure requirements under section 5-12 of the Norwegian Securities Trading Act.

How AI legalese decoder Can Help

In the context of financial reports and disclosures, understanding complex legal language can be overwhelming. This is where the AI legalese decoder can provide significant assistance. It simplifies jargon-heavy legal documents, making them more accessible and easier to understand for shareholders, stakeholders, and the general public. By utilizing this AI tool, Vistin Pharma and others can ensure that critical information is communicated clearly, fostering transparency and trust.

The AI legalese decoder not only aids in understanding regulations and obligations but also helps companies ensure compliance, reducing the risk of misunderstandings that can lead to legal repercussions. In a fast-paced financial environment, such tools are invaluable for maintaining clarity and informed decision-making.

Attachments

Please find the relevant attachments for your reference.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link